The study, which involved 175 participants, showed significant reductions in key cardiovascular risk markers, with a 78% reduction in high-sensitivity C-reactive protein observed in patients treated ...
Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the ...
Ventyx Biosciences (VTYX) announced that the Company added two experts to their advisory board and provided an update to its ongoing Phase 2 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback